Brokers Offer Predictions for NAMS FY2024 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at HC Wainwright issued their FY2024 earnings estimates for NewAmsterdam Pharma in a report issued on Monday, December 30th. HC Wainwright analyst E. Arce expects that the company will post earnings per share of ($1.64) for the year. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.

Several other research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $38.17.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $25.96 on Wednesday. NewAmsterdam Pharma has a 1 year low of $11.57 and a 1 year high of $27.29. The stock has a 50 day simple moving average of $22.39 and a 200-day simple moving average of $19.30.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in NewAmsterdam Pharma by 176.9% during the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the period. Barclays PLC grew its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Geode Capital Management LLC grew its holdings in shares of NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares during the period. M&T Bank Corp increased its position in shares of NewAmsterdam Pharma by 54.1% in the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock valued at $454,000 after buying an additional 9,593 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after buying an additional 628,251 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insider Activity

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84. Following the completion of the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. The trade was a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 446,730 shares of company stock valued at $11,438,695 over the last three months. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.